(Q24243564)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Seretide for obstructive lung disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Toward a consensus definition for COPD exacerbations

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

The Canadian Optimal Therapy of COPD Trial: design, organization and patient recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Salmeterol/fluticasone propionate in a Single Inhaler Device versus theophylline+fluticasone propionate in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Relationship between respiratory symptoms and medical treatment in exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Inhalation combination therapy in chronic obstructive lung disease. TRISTAN-study

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164185

Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD

29 November 2018

1 reference

12 December 2020

Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages

1 reference

12 December 2020

Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction

1 reference

12 December 2020

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

1 reference

12 December 2020

[Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)]

1 reference

12 December 2020

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society

1 reference

12 December 2020

Quality of life changes in COPD patients treated with salmeterol

1 reference

12 December 2020

Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking

1 reference

12 December 2020

Additive effects of salmeterol and fluticasone or theophylline in COPD

1 reference

12 December 2020

Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia

1 reference

12 December 2020

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003794.PUB3

7 January 2021